FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)

Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (IST)

Regulatory action underscores the treatment poten... Biopharmaceuticals, FDA Novartis, Promacta, eltrombopag, aplastic anemia, TPO receptor

Source: HSMN NewsFeed - May 30, 2018 Category: Pharmaceuticals Source Type: news